» Articles » PMID: 12749252

Radiofrequency Ablation of Hepatocellular Carcinoma in Cirrhotic Patients

Overview
Specialty Gastroenterology
Date 2003 May 17
PMID 12749252
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: Radiofrequency ablation is useful for local destruction of primary and secondary hepatic tumors. However there is little information about long-term outcome for patients with hepatocellular carcinoma and cirrhosis. The aims of this study included the analysis of efficacy in local control of tumors, patterns of recurrence and survival rate related to severity of cirrhosis and tumor features.

Methodology: From January 1998 to January 2001 we ablated 65 hepatocellular carcinomas in 53 patients with cirrhosis. Cirrhosis was related to HCV, HBV and alcohol intake in 32, 4 and 17 patients, respectively. According to Child-Pugh classification 24 and 29 patients belong to A and B class, respectively. Patients in Child-Pugh C class were excluded from the study. The mean diameter of lesions was 4 cm (range: 1-7 cm). In all cases radiofrequency ablation was performed with the percutaneous approach under ultrasound guidance. Treatment efficacy was estimated with dual phase computed tomography and alpha-fetoprotein dosage.

Results: Complete necrosis rate after first treatment was 90.9, 74.4 and 36.4% in hepatocellular carcinoma smaller than 3 cm, between 3 and 5 cm and larger than 5 cm, respectively (p = 0.01). After multiple treatment complete necrosis was achieved in 100, 93 and 63.6% (p = 0.01). The mean number of treatments was 1.5 (range: 1-4) per patients. Four lesions of 58 (6.8%) developed local recurrence during a mean follow-up of 18 months. No local recurrence was observed in tumors smaller than 4 cm. New tumors were observed in 15 patients (28.3%). There were no treatment-related deaths and 11 patients (20.7%) suffered minor complications. The survival rate of patients after treatment was 87, 63 and 45% at 12, 24 and 36 months, respectively. Survival was significantly related to Child-Pugh class (p = 0.01).

Conclusions: Radiofrequency ablation is a safe and effective treatment of hepatocellular carcinoma smaller than 5 cm with complete necrosis in most lesions. No local recurrences were observed in lesions smaller than 4 cm. After 3 years survival was 83% in Child-Pugh A cirrhotic patients and 31% in Child-Pugh B patients.

Citing Articles

Advances and Future Directions in the Treatment of Hepatocellular Carcinoma.

Gosalia A, Martin P, Jones P Gastroenterol Hepatol (N Y). 2017; 13(7):398-410.

PMID: 28867968 PMC: 5572970.


Effect of treatment support on preventing local recurrence of hepatocellular carcinoma directly adjacent to the diaphragm.

Ishikawa T, Imai M, Ko M, Sato H, Nozawa Y, Sano T Mol Clin Oncol. 2017; 7(1):61-66.

PMID: 28685077 PMC: 5492694. DOI: 10.3892/mco.2017.1257.


Differences in Patient Characteristics and Midterm Outcome Between Asian and European Patients Treated with Radiofrequency Ablation for Hepatocellular Carcinoma.

Burgmans M, Too C, Fiocco M, Kerbert A, Lo R, Schaapman J Cardiovasc Intervent Radiol. 2016; 39(12):1708-1715.

PMID: 27671151 PMC: 5097094. DOI: 10.1007/s00270-016-1462-7.


Comparative analysis of intraoperative radiofrequency ablation versus non-anatomical hepatic resection for small hepatocellular carcinoma: short-term result.

Yune Y, Kim S, Song I, Chun K Korean J Hepatobiliary Pancreat Surg. 2015; 19(4):173-80.

PMID: 26693237 PMC: 4683920. DOI: 10.14701/kjhbps.2015.19.4.173.


Complications after percutaneous ablation of liver tumors: a systematic review.

Lahat E, Eshkenazy R, Zendel A, Zakai B, Maor M, Dreznik Y Hepatobiliary Surg Nutr. 2014; 3(5):317-23.

PMID: 25392844 PMC: 4207846. DOI: 10.3978/j.issn.2304-3881.2014.09.07.